These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 29683099)

  • 1. Identifying Potential Therapeutics for Osteoporosis by Exploiting the Relationship between Mevalonate Pathway and Bone Metabolism.
    Hasan WNW; Chin KY; Jolly JJ; Ghafar NA; Soelaiman IN
    Endocr Metab Immune Disord Drug Targets; 2018; 18(5):450-457. PubMed ID: 29683099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
    Luckman SP; Hughes DE; Coxon FP; Graham R; Russell G; Rogers MJ
    J Bone Miner Res; 1998 Apr; 13(4):581-9. PubMed ID: 9556058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting WNT signaling in the treatment of osteoporosis.
    Baron R; Gori F
    Curr Opin Pharmacol; 2018 Jun; 40():134-141. PubMed ID: 29753194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. γ-Tocotrienol protects against ovariectomy-induced bone loss via mevalonate pathway as HMG-CoA reductase inhibitor.
    Deng L; Ding Y; Peng Y; Wu Y; Fan J; Li W; Yang R; Yang M; Fu Q
    Bone; 2014 Oct; 67():200-7. PubMed ID: 25019595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Independent pathways in the modulation of osteoclastic resorption by intermediates of the mevalonate biosynthetic pathway: the role of the retinoic acid receptor.
    van Beek E; Löwik C; Karperien M; Papapoulos S
    Bone; 2006 Feb; 38(2):167-71. PubMed ID: 16165408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition.
    Dunford JE
    Curr Pharm Des; 2010; 16(27):2961-9. PubMed ID: 20722615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates: from bench to bedside.
    Russell RG
    Ann N Y Acad Sci; 2006 Apr; 1068():367-401. PubMed ID: 16831938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
    van beek E; Löwik C; van der Pluijm G; Papapoulos S
    J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo.
    Hughes A; Rogers MJ; Idris AI; Crockett JC
    Calcif Tissue Int; 2007 Nov; 81(5):403-13. PubMed ID: 17982704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the possible mechanisms of action of tocotrienol - a potential antiosteoporotic agent.
    Chin KY; Mo H; Soelaiman IN
    Curr Drug Targets; 2013 Dec; 14(13):1533-41. PubMed ID: 23859472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins and bone formation.
    Garrett IR; Gutierrez G; Mundy GR
    Curr Pharm Des; 2001 May; 7(8):715-36. PubMed ID: 11405194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One year in review 2018: progress in osteoporosis treatment.
    Figliomeni A; Signorini V; Mazzantini M
    Clin Exp Rheumatol; 2018; 36(6):948-958. PubMed ID: 30526765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins and protein prenylation in cancer cell biology and therapy.
    Garcia-Ruiz C; Morales A; Fernandez-Checa JC
    Anticancer Agents Med Chem; 2012 May; 12(4):303-15. PubMed ID: 22413970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
    Staal A; Frith JC; French MH; Swartz J; Güngör T; Harrity TW; Tamasi J; Rogers MJ; Feyen JH
    J Bone Miner Res; 2003 Jan; 18(1):88-96. PubMed ID: 12510809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mevalonate Cascade and its Regulation in Cholesterol Metabolism in Different Tissues in Health and Disease.
    Hashemi M; Hoshyar R; Ande SR; Chen QM; Solomon C; Zuse A; Naderi M
    Curr Mol Pharmacol; 2017; 10(1):13-26. PubMed ID: 26758949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological agents and natural compounds: available treatments for osteoporosis.
    Martiniakova M; Babikova M; Omelka R
    J Physiol Pharmacol; 2020 Jun; 71(3):. PubMed ID: 32991310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
    Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
    Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins, fracture risk, and bone remodeling.
    Luisetto G; Camozzi V
    J Endocrinol Invest; 2009; 32(4 Suppl):32-7. PubMed ID: 19724164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simvastatin suppresses leptin expression in 3T3-L1 adipocytes via activation of the cyclic AMP-PKA pathway induced by inhibition of protein prenylation.
    Maeda T; Horiuchi N
    J Biochem; 2009 Jun; 145(6):771-81. PubMed ID: 19254925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key Enzymes for the Mevalonate Pathway in the Cardiovascular System.
    Zhang C; Jin DD; Wang XY; Lou L; Yang J
    J Cardiovasc Pharmacol; 2021 Feb; 77(2):142-152. PubMed ID: 33538531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.